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2The purpose of this study was to use various dosimetrical indices to determine the best IMRT 
modality technique for treating patients with prostate cancer. Ten patients with prostate cancer 
were included in this study. Intensity modulated radiation therapy plans were designed to include 
different modalities, including the linac step and shoot, Tomotherapy, RapidArc, and Proton 
systems. Various dosimetrical indices, like the prescription isodose to target volume (PITV) ratio, 
conformity index (CI), homogeneity index (HI), target coverage index (TCI), modified dose 
homogeneity index (MHI), conformation number (CN), critical organ scoring index (COSI), and 
quality factor (QF) were determined to compare the different treatment plans. Biological indices 
such as the generalized equivalent uniform dose (gEUD), based tumor control probability (TCP), 
and normal tissue complication probability (NTCP) were also calculated and used to compare the 
treatment plans. The RapidArc plan attained better PTV coverage, as evidenced by its superior 
PITV, CI, TCI, MHI, and CN values. Regarding OARs, proton therapy exhibited superior dose 
sparing for the rectum and bowel in low dose volumes, whereas the Tomotherapy and RapidArc 
plans achieved better dose sparing in high dose volumes. The QF scores showed no significant 
difference among these plans (p=0.701). The average TCPs for prostate tumors in the RapidArc, 
Linac, and Proton plans were higher than the average TCP for Tomotherapy (98.79%, 98.76%, 
and 98.75% vs. 98.70%, respectively). Regarding the rectum NTCP, RapidArc showed the most 
favorable result (0.09%), whereas Linac resulted in the best bladder NTCP (0.08%).
PACS number: 87.53.Tf
Keywords: Prostate cancer, Intensity modulated radiation therapy (IMRT), Dosimetrical index, 
Radiobiological index.
E-mail: sukmp@korea.ac.kr
Fax: + 82-2-927-1419
3I. INTRODUCTION
Prostate cancer is the most common cancer worldwide; moreover, the incidence of prostate cancer 
has been rapidly increasing in all industrialized nations [1]. Since the introduction of advanced 
radiation therapy (RT) techniques such as intensity-modulated radiation therapy (IMRT), several 
studies have reported that IMRT yields excellent results and is particularly suited to the treatment of 
prostate cancer. This is because IMRT not only enables dose escalation in the prostate, but also 
simultaneously spares normal tissues such as the bladder and rectum [2-4]. Moreover, IMRT results in 
significantly less toxicity and significantly more prostate dose escalation compared with 3 dimensional 
conformal radiotherapy (3DCRT) plans [5-7]. Therefore, IMRT is being increasingly used in the 
treatment of prostate cancer. 
Various modalities of IMRT delivery systems have been developed, such as linear accelerator based-
IMRT systems, the Tomotherapy® system (Hi-Art system, Accuray Inc., Madison, WI, USA), the 
RapidArc system (Varian Medical System Inc., Palo Alto, CA, USA), the CyberKnife system (Accuray 
Inc., Sunnyvale, CA, USA), and proton systems. 
Generally, IMRT delivery systems are classified into two different categories: fixed-gantry and arc-
based. Fixed-gantry IMRT systems use a number of fixed beam directions with a multi-leaf collimator; 
these systems are based on the linear accelerator (LINAC). Step-and-shoot and dynamic (sliding 
window) IMRT techniques are some of these systems. One notable example of arc-based IMRT is the 
Tomotherapy® system, which can be divided into the TomoDirect and TomoHelical IMRT techniques 
[8-10]. In the step-and-shoot technique, a radiation beam is produced by the superposition of a number 
of static segments. The leaves of the MLC stay stationary during beam delivery; moreover, the beam is 
off when the MLC leaves and travels from one segment to another [11, 12]. The TomoDirect system 
allows the beam irradiation to be focused at discrete angles with a fixed gantry, which is particularly 
suited to certain clinical situations in which the beam arrangement is constrained to a limited number of 
pre-established directions using a continuous couch and MLC movement[13-15]. The TomoHelical 
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angle, coupled with continuous rotation of the gantry around the patient [16]. The CyberKnife is a 
novel beam delivery system that is well suited for treating the prostate. This system consists of a 6 MV 
linear accelerator that is mounted on a robotic arm, a pair of X-ray imaging systems, and several 
hundred noncoplanar beams [17, 18]. Proton therapy is also increasingly being used to treat prostate 
cancer. Moreover, proton therapy appears to result in significant dose savings to critical organs; proton 
therapy also results in decreased treatment toxicity and improved treatment efficacy due to the sharp 
characteristic Bragg peak of proton beams [19-21].
Several studies have compared treatment plans using different IMRT modalities by determining their 
dosimetric indices for prostate cases [17, 19, 22]. Ceylan et al. demonstrated that the CyberKnife can 
deliver high doses to the prostate compared with LINAC-based IMRT plans; however, the PTV 
coverage between these two modalities is not very significant [17]. Schwarz et al. compared helical 
tomotherapy and intensity modulated proton therapy (IMPT) techniques for treating prostate cancer. 
This study confirmed that IMPT provides better savings to OARs, in particular the bladder and penile 
bulb, compared with helical tomotherapy. However, both of these modalities offer good target coverage 
[22]. Similarly, Cotter et al. compared proton radiotherapy versus IMRT for pediatric prostate 
rhabdomyosarcoma. This study provides evidence of significant dose savings to normal structures with 
proton radiotherapy compared to IMRT [19]. As described above, several studies have compared the 
results of various IMRT delivery techniques. However, studies comparing prostate cancer outcomes for 
treatment plans using the Linac step and shoot technique, Tomotherapy, RapidArc, or proton modalities 
are limited. 
The purpose of this study was thus to determine the best modality out of four possible modalities for 
treating patients with prostate cancer. To this end, we compared the dosimetric physical indices, EUD-
based TCP scores, and EUD-based NTCP scores for different IMRT plans used to treat ten different 
patients with prostate cancer.
5II. Materials and Methods
A. Patient characteristics
Ten consecutive patients treated with tomotherapy for prostate cancer at our institution were 
included in this study. All patients were male, with 8 patients aged older than 65 years. All patients wre 
diagnosed as clinical stage II or III prostate cancer and no patients received nodal irradiation. 
B. Planning CT scans and contouring PTVs and OARs
All patients underwent computed tomography (CT) scans for treatment planning on a CT simulator 
(Philips Medical System, Eindhoven, The Netherlands). Computed tomography images were acquired 
using a CT Simulator with 2 mm axial slice thickness. All CT data were transferred to a treatment 
planning system (TPS, Eclipse version 8.9, Varian Medical System Inc., Palo Alto, CA) with inverse 
planning. All clinical target volumes (CTVs), planning target volumes (PTVs), and organs at risk 
(OARs) were contoured on TPS. Organs considered to be at risk included the bladder, rectum, hip joint, 
and bone marrow. The CTV was defined as the region of prostate cancer. The PTV was determined by 
adding a 2 mm margin to the CTV in order to compensate for potential movements such as those 
occurring during treatment setup and/or breathing motions.
C. Dose description
The prescription dose for each patient was designed so that 95% of the PTV received at least 77 Gy,
with 35 fractions of 1.8 Gy administered daily. Dose constraints for OARs were determined based on 
the method described by Emami [23] and QUANTEC data [24]. The following dose constraints for 
OARs were used: mean dose for the bladder, 40 Gy; mean dose for the rectum, 40 Gy; mean dose for 
the hip joint, 50 Gy; mean dose for the bone marrow, 50 Gy.
D. Planning techniques
D.1. LINAC-based IMRT treatment plan
A linear accelerator (Clinac iX, Varian Medical System Inc., Palo Alto, CA, USA) equipped with a 6 
MV photon beam was used for step-and-shoot IMRT planning. Step-and-shoot IMRT treatment plans 
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modulation was performed using a 120-leaf MLC. The pencil beam algorithm was used to calculate the 
dose for each patient.
D.2. TomoHelical IMRT plan
Planning CT data with RT structures were transferred from Eclipse TPS to Pinnacle TPS; the CT 
data were then imported into the TomoTherapy Planning station (Hi-Art version 1.1.1, Accuray Inc., 
Madison, WI, USA) to generate the TomoHelical IMRT plans. The field width, pitch, and modulation 
factor values were 1.05 cm, 0.287, and 2.5, respectively. A calculation grid was applied according to 
standard procedures. The pencil beam algorithm was used for dose calculation.
D.3. RapidArc plan
To generate RapidArc plans, the Eclipse treatment planning system (Version 8.9, Varian Medical 
System Inc., Palo Alto, CA, USA) was used. The AAA algorithm was used for dose calculation
D.4. Proton plan
For proton treatment planning, CT data were imported into the proton treatment planning system 
(Eclipse Version 8.03, Varian Medial System Inc., Palo Alto, CA, USA). All proton treatment plans 
used one beam and the passive scattering mode. The gantry angle was 270°, and the AAA algorithm 
was used for dose calculation.
E. Treatment plan analysis
E.1. Dosimetrical index
Several quantitative evaluation tools were used to compare plans with one another. The following 
aspects of the plans were compared: prescription isodose to target volume (PITV) ratio, homogeneity 
index (HI), conformity index (CI), target coverage index (TCI), modified dose homogeneity index 
(MHI), conformity number (CN) for the PTV, maximum dose, mean dose, dose volume histogram 
(DVH), and critical organ scoring index (COSI) for the OAR. The PITV ratio was obtained by dividing 
the prescription isodose surface volume by the target volume [25]. The CI, which is defined as the ratio 
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dose, is generally used to indicate the portion of the prescription dose that is delivered inside the PTV 
[26]. The HI is the ratio of the maximum dose delivered to the PTV to the prescription dose to the PTV. 
The TCI refers to the exact coverage of the PTV in a treatment plan for a given prescription dose [27]. 
The MHI is similar to the HI, except that it is expressed as the 95% dose coverage value divided by the 
5% dose coverage value [27]. The CN is a relative measurement of the dosimetric target coverage and 
the sparing of normal tissues in a given treatment plan [28]. The CN is expressed as: CN = TCI × CI = ௉்௏ುವ௉்௏ × ௉்௏ುವ௉ூ௏            (1)
where PTVPD refers to the PTV coverage at the prescription dose and PIV represents the prescription 
isodose surface volume. The COSI index takes into account both the target coverage and the critical 
organ irradiation [29]. The main advantage of this index is its ability to distinguish between different 
critical organs.  The COSI is expressed as:COSI = 1 − 	∑ ݓ௜௡ଵ ௏೔(ை஺ோ)ಭ೟೚೗்஼               (2)
where V(OAR)>tol is the fraction of the volume of the OAR that receives more than a predefined 
tolerance dose, and TCV is the volumetric target coverage, which is defined as the fractional volume of 
PTV covered by the prescribed isodose. 
The modified COSI is expressed as:mCOSI = 	 ∑ ܹ݅௡௜ୀଵ ቂ஼ைௌூଵ଴ା஼ைௌூଶ଴ା⋯ା஼ைௌூ଼଴଼ ቃ       (3)
Although the COSI index focuses only on the OARs that receive high dose region volumes, the 
modified COSI considers both high dose regions and low dose regions.  
The maximum dose, mean dose, and DVH were used to quantitatively evaluate the dose distributions 
in the rectum and bladder. The DVH index included V5, V10, V20, V30, V40, V50, V60, and V70.
E.2. Quality factor (QF)
A novel dosimetrical index that can evaluate the quality of the entire plan, named the quality factor 
8(QF), was introduced in this study. The QF of a plan can be analytically expressed as:QF = 	 [2.718 exp(−∑ ௜ܹ ௜ܺே௜ୀଵ )]            (4)
In the above equation, Xi represents all of the PTV indices used in this study, including the PITV, CI, 
HI, TCI, MHI, CN, and COSI. The values of the weighting factor (Wi) can be adjusted between 0 and 1 
for all relatively weighted indices for a user-defined number of indices (N). In this study, a weighting 
factor of 1 was used for all separate indices. Thus, the QF was mainly used to compare the conformity 
of plans throughout the various trials of a treatment [30].
E.3. Biological index
For radiobiological model-based plan evaluation, Niemierko’s equivalent uniform dose (EUD)-based 
NTCP and TCP models were used [31, 32]. First, the DVHs from each plan were exported from the 
appropriate treatment planning system (TPS) for each modality. Then, the DVHs were imported into 
MATLAB version R2012a (The MathWorks, Inc., Natick, Massachusetts) for TCP and NTCP 
modeling analysis. 
According to Neimierko’s phenomenological model, the EUD is defined as: EUD = [∑ ( ௜ܸܧܳܦ௜௔)௜ୀଵ ]భೌ               (5)
where a is a unitless model parameter that is specific to the nominal structure of the tumor of interest, 
and vi is a unitless parameter that represents the i
th partial volume receiving dose Di in Gy [31]. Since 
the relative volume of the whole structure of interest corresponds to 1, the sum of all the partial 
volumes vi will equal 1. Furthermore, in equation (4), the EQD is the biologically equivalent physical 
dose of 2 Gy and is defined as: 
EQD = D × ቆഀഁା ವ೙೑ቇቀഀഁାଶቁ                 (6)
where nf and df =D/nf are the number of fractions and the dose per fraction size of the treatment 
course, respectively. In this equation, α/β is the tissue-specific linear quadratic (LQ) parameter of the 
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Niemierko’s TCP [31] is defined as: TCP = ଵଵା	ቀ೅಴ವఱబಶೆವ ቁംఱబ         (7)
where TCD50 is the tumor dose to control 50% of the cancer cells when the tumor is homogeneously 
irradiated, and γ50 is a unitless model parameter that is specific to the tumor of interest and describes 
the slope of the dose response curve. 
Niemierko’s NTCP [32] is defined as: NTCP = ଵଵା	ቀ೅ವఱబಶೆವ ቁംఱబ         (8)
where TD50 is the tolerance dose of a 50% complication rate at a specific time (e.g. 5 years in the 
Emami et al. normal tissue tolerance data [23]) for an entire organ of interest; this parameter also 
describes the slope of the dose response curve. 
For the prostate tumors in this study, the EUD and TCP values were calculated using an α/β value of 
1.2. For the OARs, the α/β values used were 3.9 and 8.0 for the rectum and bladder, respectively [31]. 
A complete list of the radiobiological parameters used in this study is shown in Table 5.
D.3. Statistical analysis
Data are reported as means ± SDs. To determine whether the differences between dosimetrical and 
biological indices were significant, the Kruskal-Wallis test and the Mann-Whitney test were performed. 
All calculations were performed using SPSS software, version 19.0. Differences were considered 
significant for p values < 0.05.
III. Results
A. Dosimetrical index
A.1. PTV
10
All investigated indices for the PTVs are shown in Table 1, and are expressed as mean values ± 
standard deviations (SDs). Regarding the different PTV indices, the proton plan had relatively 
favorable results for the PITV and HI (0.999 and 1.056; p = 0.008 and p = 0.002, respectively) 
compared with other modalities. In contrast, the Linac and Rapidarc plans exhibited better results with 
respect to the CI and CN (0.953 and 0.905; p = 0.028 and p = 0.038, respectively). Furthermore, the 
Tomotherapy plan yielded a slightly better MHI value (0.960) compared with the others. However, the 
TCI and MHI indices were not significantly different among any of the modalities examined. The 
different indices are compared among these four modalities in table 3. The proton plan showed 
significant discrepancies in almost all PTV indices (P < 0.05). However, the TCI and MHI values for 
the proton plan were not significantly different from those of the tomotherapy, Linac, and Rapidarc 
plans (P > 0.05). The majority of the PTV indices were not significantly different among the 
tomotherapy, Linac, and Rapidarc plans, with the exception of the HI values for the Linac versus the 
Rapidarc plans (P = 0.006).
A.2. OAR
All proton, Tomotherapy, Linac, and Rapidarc treatment plans met the criteria for normal tissue 
constraints in this study. The mean values of volume for the normal organs were 68.11 cm3, 106.43 cm3, 
456.51 cm3, 24.86 cm3, and 578.83 cm3 for the rectum, bladder, bowel, hip joint, and bone marrow, 
respectivel1. Detailed dosimetric indices for the OARs are shown in Table 2. Regarding the OAR 
indices, the proton plan showed relatively favorable results since it incurred lower dose volumes (49.35, 
43.39, 39.39, 36.23, and 30.88 for RV5, RV10, RV15, RV20, and RV30; 72.01, 65.98, 61.82, 58.30, 
and 52.03 for BV5, BV10, BV15, BV20, and BV30, respectively). However, the differences between 
the proton plan and the other plans decreased when the indices for higher dose volumes (RV50, RV60, 
and RV70; BV50, BV60, and BV70) were examined, as shown in Table 4. For the maximum dose in 
both the rectum and the bladder, all modalities showed similar doses (78.20 Gy –80.16 Gy for the 
rectum, p = 0.116; 78.75 Gy –81.13 Gy for the bladder, p = 0.002). In contrast, arc therapies such as 
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the Tomotherapy and Rapidarc approaches resulted in relatively larger percentages of volume in lower 
dose volumes (RV5 to RV 30); however, these differences were less apparent in higher dose volumes 
(RV50 to RV 70) (Table 4). The COSI index takes into account both the target coverage and the OAR 
dose (V10 to V80 in this study) in critical structures. As shown in Table 1, the Linac and Proton plan 
exhibited relatively favorable COSI results compared with the Rapidarc, and Tomotherapy plans (0.734 
and 0.708 versus 0.698 and 0.687, respectively; p=0.630).
B. Quality factor
The quality factor takes into account all of the dosimetrical indices. As shown in Table 1 the Linac 
and Rapidarc plans had the most favorable overall results (1.066 ± 0.011 and 1.068 ± 0.080, 
respectively) compared with the proton and Tomotherapy plans (1.073 ± 0.015 and 1.080 ± 0.032, 
respectively) (p =0.701).
C. Biological index
C.1. PTV
The average EUD values for the prostate tumors in the Linac and proton plans (85.029 ± 0.449 Gy 
and 84.766 ± 0.479 Gy, respectively) were slightly higher than those in the Tomotherapy and Rapidarc 
plans (83.339 ± 0.575 Gy and 84.686 ± 0.427 Gy, respectively), which were showed in table 5. 
Although these differences were slight, they were statistically significant (p<0.001). Furthermore, the 
average TCP values for the prostate tumors were significantly higher in the Linac and proton plans 
(98.903 ± 0.381% and 98.766 ± 0.027%, respectively) compared with the Tomotherapy and Rapidarc 
plans (98.680 ± 0.036% and 98.761 ± 0.025%, respectively) (p<0.001).
C.2. Rectum
The average EUD values for the rectum in the proton and Tomotherapy plans (54.997 ± 8.826 Gy 
and 55.590 ± 5.440 Gy, respectively) were slightly higher than the values for the Linac and Rapidarc 
plans (52.209 ± 4.702 Gy and 51.592 ± 3.555 Gy, respectively); however, these differences were not 
statistically significant (p=0.112). The average NTCP values for the rectum in the proton and 
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Tomotherapy plans (1.094 ± 1.370% and 0.530 ± 0.422%, respectively) were higher than those in the 
Linac and Rapidarc plans (0.191 ± 0.167% and 0.129 ± 0.095%, respectively); however, these values 
were not significantly different (p=0.109) (table 5).
C.3. Bladder
The average EUD values for the bladder in the proton and Tomotherapy plans (45.337 ± 6.864 Gy 
and 41.044 ± 7.698 Gy, respectively) were slightly higher than those in the Linac and Rapidarc plans 
(34.348 ± 6.351 Gy and 36.886 ± 6.558 Gy, respectively) (p=0.016). The average NTCP values for the 
bladder in the proton and Tomotherapy plans (0.065 ± 0.144% and 0.017 ± 0.026%, respectively) 
showed in table 5, were higher than those in the Linac and Rapidarc plans (0.002 ± 0.005% and 0.004 ± 
0.007%, respectively); these differences were statistically significant (p=0.049).
IV. Discussion
Here we used both dosimetric indices and EUD-based TCP and NTCP models to compare various 
IMRT plans (conventional LINAC-based IMRT, TomoDirect, TomoHelical, RapidArc, and proton 
techniques) for treating prostate cancer. Both dosimetrical indices and biological models revealed that 
the Linac and Rapidarc plans were superior to the proton and Tomotherapy plans, at least in the context 
of prostate radiotherapy. 
As shown in Table 1 and 3, the proton therapy plan provided a slightly greater PITV, and the dose 
conformity in this plan was almost equal to the PTV. However, the plans with other modalities also 
achieved the dosimetric criteria for the PTV. Rao et al. reported that the homogeneous dose distribution 
within the PTV was slightly increased compared with the VMAT [33]. In contrast, Pasquier et al. 
reported that the HT provided a more accurate HI value compared with the VAMT [34]. 
The inherent arc therapy nature of the Tomotherapy and Rapidarc plans enabled them to produce 
highly conformal dose distributions over the targets, as evidenced by our findings that these plans 
yielded better PTV indices in terms of the PITV, CI, TCI, MHI, and CN. In accordance with our 
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findings, Poon et al. reported that the Rapidarc plan was more conformal than static field IMRT for 
PTVs in high risk prostate cases [35]. 
Conversely, due to the rotation that is inherent in arc therapy approaches, substantial volumes of 
normal tissues adjacent to the tumors received low doses of irradiation when the doses were spread 
over a span of 360°. As shown in Table 2, arc therapies like Tomotherapy and Rapidarc resulted in 
larger percentages of volume receiving radiation in lower target dose volumes (RV5 to RV 30). These 
differences were less apparent in higher dose volumes (RV50 to RV 70) (Table 4).
As shown in Table 1, the proton therapy plan yielded reduced doses to the bladder (RV5 to RV20) 
and the rectum (BV5 to BV30) compared with other plans, at least when the target volumes received 
low doses. Our results are similar to those reported in other treatment planning studies [19, 20, 36]. The 
Linac-based IMRT plan also significantly reduced the dose received by the rectum (RV30 to RV 70) 
and bladder (BV50 to BV70) compared with the other modalities. This result conflicts with a previous 
study by Rao et al., which reported that the IMRT and VMAT plans were not significantly different in 
their sparing of OARs [33]. This discrepancy might result from study-to-study treatment plan variations, 
or the ways in which the treatment plans were designed. 
To identify the most balanced plan in terms of both PTV coverage and OAR sparing, we used the 
quality factor (QF) to evaluate the quality of each treatment plan [30]. This measurement takes into 
account all of the PTV and OAR indices used in this study, including the PITV, CI, HI, TCI, MHI, CN, 
and COSI. The values of the weighting factor can be adjusted between 0 and 1 for all relatively 
weighted indices for a user-defined number of indices. Thus, the QF is mainly used to compare the 
conformity of different plans in the various trials of a treatment. As shown in Table 1, the RapidArc 
and Linac-based plans exhibited slightly greater QFs compared with the other modalities; the 
Tomotherapy plan exhibited the lowest QF score. 
The method that we used to evaluate the different treatment plans does have some inherent 
limitations. Since the PTV and OAR values were weighted equally, the importance of each factor in the 
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total plan quality may not have been fully considered. To determine the most appropriate weighting 
value to use for determining the QF, additional studies with large sample sizes that also include clinical 
outcome information on certain treatment sites, in addition to more advanced statistical analysis, are 
needed.
For outcome-based radiobiological evaluation of treatment plans, we used Niemierko’s EUD-based 
TCP and NTCP models [31, 32]. The largest difference in NTCP values for the rectum was between 
the proton and Rapidarc plans; Similarly, the NTCP values for the bladder were the most different 
between the proton and Linac plans. Currently, adequate clinical radiobiological modeling data on 
multimodality planning for prostate cancer are lacking. This may be due to the current standard practice 
of evaluating treatment plans using dosimetrical DVH parameters alone. Using the NTCP model, 
Widesott et al. compared the treatment planning results for treating prostate cancer with the 
Tomotherapy and proton IMRT techniques [37]. This study found that the proton plan yielded more 
favorable NTCP results for the rectum. 
In this study, the treatment, dose calculation, and optimization time were not included in the QF and 
thus did not contribute to the plan quality metric. Rao et al. reported that one major advantage of the 
VMAT approach compared with the HT and IMRT plans is its fast beam delivery time [34]. Oliver et 
al. demonstrated that the RapidArc plan has the lowest beam delivery time compared with both the 
IMRT and Tomotherapy plans [38]. We confirmed that the proton plan can reduce the treatment time; 
however, the overall quality of the proton plan was not significantly different compared with the other 
modalities. This may be because the proton plan is not an IMRT plan technique, and it only uses one 
port for treatment. However, Rao et al. found that decreased treatment times can reduce the amount of 
intrafraction motion during radiation therapy, and can thus improve the overall biological effectiveness 
of a plan [26]. Therefore, future studies comparing plans with different modalities will incorporate 
treatment, dose calculation, and optimization time into the QF calculation.
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III. CONCLUSION
Here we used dosimetric indices, in addition to a plan evaluation scoring index developed in-house, 
to compare different IMRT treatment plans using conventional LINAC-based IMRT, the TomoHelical 
system, the RapidArc system, and proton techniques. We found that, regarding PTV coverage, arc 
therapies such as the RapidArc system can attain better target coverage and yielded better PITV, CI, 
TCI, MHI, and CN values. For OARs, proton therapy is a superior technique for achieving optimum 
dose sparing for the rectum and bowel in low dose volumes; however, arc therapies such as the 
Tomotherapy and RapidArc systems can achieve better dose sparing in high dose volumes. Similarly, 
Linac and Rapidarc showed advantages in terms of BED-based TCP and NTCP. Along these lines, 
considering both the dosimetrical and biological indices, the RapidArc and Linac IMRT approaches 
were superior to the other techniques for prostate cancer radiotherapy.
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Table 1. Dosimetrical indices of PTVs.
Index Proton Tomotherapy Linac Rapidarc p-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
PITV 0.999 ± 0.001 0.997 ± 0.003 0.996 ± 0.002 0.997 ± 0.003 0.000
CI 0.951 ± 0.001 0.937 ± 0.034 0.953 ± 0.003 0.953 ± 0.003 0.008
HI 1.056 ± 0.008 1.073 ± 0.020 1.060 ± 0.012 1.081 ± 0.011 0.000
TCI 0.950 ± 0 0.934 ± 0.033 0.949 ± 0.002 0.950 ± 0 0.009
MHI 0.959 ± 0.005 0.960 ± 0.010 0.956 ± 0.004 0.957 ± 0.006 0.000
CN 0.903 ± 0.001 0.876 ± 0.061 0.905 ± 0.005 0.905 ± 0.003 0.007
COSI 0.708 ± 0.082 0.687 ± 0.095 0.734 ± 0.080 0.698 ± 0.080 0.630
QF 1.073 ± 0.015 1.080 ± 0.032 1.066 ± 0.011 1.068 ± 0.080 0.701
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Table 2. Dosimetrical indices of OARs.
Index Proton Tomotherapy Linac Rapidarc p-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
RV5 49.515 ± 18.543 77.775 ± 17.254 70.513 ± 16.807 78.601 ± 17.342 0.007 
RV10 43.397 ± 17.680 65.075 ± 18.513 59.656 ± 18.793 64.872 ± 18.378 0.057 
RV15 39.396 ± 16.685 59.313 ± 18.704 51.441 ± 19.528 58.439 ± 17.937 0.115 
RV20 36.234 ± 15.881 51.147 ± 17.319 42.935 ± 17.873 48.361 ± 13.891 0.315 
RV30 30.887 ± 14.309 35.845 ± 13.506 29.191 ± 13.183 32.527 ± 8.476 0.701 
RV50 21.387 ± 11.171 15.786 ± 6.947 14.045 ± 6.605 14.057 ± 4.558 0.402 
RV60 16.101 ± 9.159 9.785 ± 5.464 9.112 ± 4.541 8.372 ± 3.243 0.243 
RV70 9.266 ± 6.365 4.219 ± 3.131 4.059 ± 2.312 3.305 ± 1.565 0.148 
RMax Dose 78.217 ± 2.246 78.442 ± 1.618 78.201 ± 1.830 78.861 ± 2.205 0.824 
BV5 72.010 ± 13.268 95.150 ± 7.413 89.672 ± 11.313 97.282 ± 5.017 0.000 
BV10 65.988 ± 13.708 83.500 ± 15.289 76.496 ± 16.346 84.304 ± 14.216 0.082 
BV15 61.829 ± 13.668 77.685 ± 19.143 66.046 ± 17.614 77.773 ± 18.676 0.203 
BV20 58.303 ± 13.596 72.374 ± 21.738 56.807 ± 16.710 71.374 ± 20.724 0.192 
BV30 52.037 ± 13.268 56.565 ± 21.449 42.311 ± 13.750 54.565 ± 19.329 0.309 
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BV50 38.812 ± 10.783 23.341 ± 9.871 21.131 ± 8.267 22.584 ± 8.608 0.005 
BV60 31.155 ± 9.193 13.121 ± 6.632 12.712 ± 5.354 12.511 ± 5.514 <0.001
BV70 20.864 ± 7.074 5.372 ± 3.924 4.960 ± 2.824 4.939 ± 2.620 <0.001
BMax Dose 79.811 ± 0.687 79.101 ± 1.218 78.756 ± 0.877 79.555 ± 1.417 0.089 
Abbreviations: RVX = relative rectal volume of receiving higher than X Gy, BVX = relative bladder volume of receiving higher than X Gy, 
Rmax dose = maximum dose to rectum, BMax dose = maximum dose to bladder.
21
Table 3. Comparison of PTV indices for each modality.
Index Proton Tomotherapy Linac
p-value p-value p-value
PITV
Tomotherapy 0.019 Proton > Tomotherapy
Linac 0.001 Proton > Linac 0.472 Tomotherapy > Linac
Rapidarc 0.021 Proton > Rapidarc 0.970 Tomotherapy < Rapidarc 0.384 Linac < Rapidarc
CI
Tomotherapy 0.028 Proton > Tomotherapy
Linac 0.008 Proton < Linac 0.450 Tomotherapy < Linac
Rapidarc 0.025 Proton < Rapidarc 0.970 Tomotherapy < Rapidarc 0.496 Linac < Rapidarc
HI
Tomotherapy 0.028 Proton > Tomotherapy
Linac 0.325 Proton > Linac 0.096 Tomotherapy < Linac
Rapidarc 0.001 Proton > Rapidarc 0.448 Tomotherapy > Rapidarc 0.006 Linac > Rapidarc
TCI
Tomotherapy 0.136 Proton < Tomotherapy
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Linac 0.317 Proton < Linac 0.328 Tomotherapy < Linac
Rapidarc 0.543 Proton < Rapidarc 0.347 Tomotherapy < Rapidarc 0.957 Linac < Rapidarc
MHI
Tomotherapy 0.597 Proton > Tomotherapy
Linac 0.290 Proton < Linac 0.571 Tomotherapy > Linac
Rapidarc 0.226 Proton < Rapidarc 0.495 Tomotherapy > Rapidarc 0.910 Linac < Rapidarc
CN
Tomotherapy 0.031 Proton > Tomotherapy
Linac 0.009 Proton < Linac 0.450 Tomotherapy < Linac
Rapidarc 0.044 Proton < Rapidarc 0.970 Tomotherapy < Rapidarc 0.496 Linac < Rapidarc
COSI
Tomotherapy 0.003 Proton < Tomotherapy
Linac 0.006 Proton < Linac 0.625 Tomotherapy > Linac
Rapidarc 0.018 Proton < Rapidarc 0.347 Tomotherapy > Rapidarc 0.649 Linac < Rapidarc
QF
Tomotherapy 0.023 Proton > Tomotherapy
Linac 0.009 Proton < Linac 0.059 Tomotherapy < Linac
Rapidarc 0.000 Proton < Rapidarc 0.820 Tomotherapy < Rapidarc 0.001 Linac < Rapidarc
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Table 4. Comparison of OAR indices for each modality.
Index Proton Tomotherapy Linac
p-value p-value p-value
RV5
Tomotherapy 0.005 Proton > Tomotherapy
Linac 0.028 Proton > Linac 0.226 Tomotherapy < Linac
Rapidarc 0.005 Proton > Rapidarc 0.879 Tomotherapy > Rapidarc 0.199 Linac > Rapidarc
RV10
Tomotherapy 0.019 Proton > Tomotherapy
Linac 0.096 Proton > Linac 0.406 Tomotherapy < Linac
Rapidarc 0.023 Proton > Rapidarc 0.820 Tomotherapy < Rapidarc 0.450 Linac > Rapidarc
RV15
Tomotherapy 0.041 Proton > Tomotherapy
Linac 0.326 Proton > Linac 0.257 Tomotherapy < Linac
Rapidarc 0.049 Proton > Rapidarc 0.879 Tomotherapy < Rapidarc 0.257 Linac > Rapidarc
RV20
Tomotherapy 0.112 Proton > Tomotherapy
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Linac 0.597 Proton > Linac 0.290 Tomotherapy < Linac
Rapidarc 0.174 Proton > Rapidarc 0.820 Tomotherapy < Rapidarc 0.290 Linac > Rapidarc
RV30
Tomotherapy 0.597 Proton > Tomotherapy
Linac 0.705 Proton < Linac 0.257 Tomotherapy < Linac
Rapidarc 1.000 Proton > Rapidarc 0.762 Tomotherapy < Rapidarc 0.290 Linac > Rapidarc
RV50
Tomotherapy 0.257 Proton < Tomotherapy
Linac 0.174 Proton < Linac 0.545 Tomotherapy < Linac
Rapidarc 0.151 Proton < Rapidarc 0.705 Tomotherapy < Rapidarc 0.762 Linac > Rapidarc
RV60
Tomotherapy 0.151 Proton < Tomotherapy
Linac 0.112 Proton < Linac 0.762 Tomotherapy < Linac
Rapidarc 0.070 Proton < Rapidarc 0.705 Tomotherapy < Rapidarc 0.821 Linac < Rapidarc
RV70
Tomotherapy 0.096 Proton < Tomotherapy
Linac 0.096 Proton < Linac 0.762 Tomotherapy < Linac
Rapidarc 0.041 Proton < Rapidarc 0.820 Tomotherapy < Rapidarc 0.406 Linac < Rapidarc
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RMax Dose
Tomotherapy 0.406 Proton > Tomotherapy
Linac 0.910 Proton < Linac 0.449 Tomotherapy < Linac
Rapidarc 0.705 Proton > Rapidarc 0.596 Tomotherapy > Rapidarc 0.762 Linac > Rapidarc
BV5
Tomotherapy 0.001 Proton > Tomotherapy
Linac 0.006 Proton > Linac 0.142 Tomotherapy < Linac
Rapidarc 0.000 Proton > Rapidarc 0.716 Tomotherapy > Rapidarc 0.045 Linac > Rapidarc
BV10
Tomotherapy 0.041 Proton > Tomotherapy
Linac 0.151 Proton > Linac 0.289 Tomotherapy < Linac
Rapidarc 0.034 Proton > Rapidarc 0.848 Tomotherapy > Rapidarc 0.256 Linac > Rapidarc
BV15
Tomotherapy 0.112 Proton > Tomotherapy
Linac 0.597 Proton > Linac 0.173 Tomotherapy < Linac
Rapidarc 0.112 Proton > Rapidarc 0.970 Tomotherapy > Rapidarc 0.174 Linac > Rapidarc
BV20
Tomotherapy 0.131 Proton > Tomotherapy
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Linac 0.705 Proton < Linac 0.131 Tomotherapy < Linac
Rapidarc 0.131 Proton > Rapidarc 0.820 Tomotherapy < Rapidarc 0.131 Linac > Rapidarc
BV30
Tomotherapy 0.650 Proton > Tomotherapy
Linac 0.082 Proton < Linac 0.151 Tomotherapy < Linac
Rapidarc 0.705 Proton > Rapidarc 0.940 Tomotherapy < Rapidarc 0.174 Linac > Rapidarc
BV50
Tomotherapy 0.008 Proton < Tomotherapy
Linac 0.003 Proton < Linac 0.821 Tomotherapy < Linac
Rapidarc 0.002 Proton < Rapidarc 0.879 Tomotherapy < Rapidarc 0.880 Linac > Rapidarc
BV60
Tomotherapy 0.001 Proton < Tomotherapy
Linac 0.000 Proton < Linac 0.940 Tomotherapy < Linac
Rapidarc 0.001 Proton < Rapidarc 0.940 Tomotherapy < Rapidarc 0.940 Linac < Rapidarc
BV70
Tomotherapy 0.000 Proton < Tomotherapy
Linac 0.000 Proton < Linac 0.940 Tomotherapy < Linac
Rapidarc 0.000 Proton < Rapidarc 0.879 Tomotherapy < Rapidarc 0.940 Linac < Rapidarc
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BMax Dose
Tomotherapy 0.112 Proton < Tomotherapy
Linac 0.026 Proton < Linac 0.326 Tomotherapy < Linac
Rapidarc 0.821 Proton < Rapidarc 0.324 Tomotherapy > Rapidarc 0.070 Linac > Rapidarc
Abbreviations: RVX = relative rectal volume of receiving higher than X Gy, BVX = relative bladder volume of receiving higher than X Gy, 
Rmax dose = maximum dose to rectum, BMax dose = maximum dose to bladder.
28
Table 5. Radiobiological parameters used to calculate EUD-based TCP and NTCP scores.
Organs Indices Proton Tomotherapy Linac Rapidarc p-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
PTV EUD (Gy) 84.766 ± 0.479 83.339 ± 0.575 85.029 ± 0.449 84.686 ± 0.427 0
TCP (%) 98.766 ± 0.027 98.68 ± 0.036 98.903 ± 0.381 98.761 ± 0.025 0
Rectum EUD (Gy) 54.997 ± 8.826 55.59 ± 5.44 52.209 ± 4.702 51.592 ± 3.555 0.112
NTCP (%) 1.094 ± 1.37 0.53 ± 0.422 0.191 ± 0.167 0.129 ± 0.095 0.109
Bladder EUD (Gy) 45.337 ± 6.864 41.044 ± 7.698 34.338 ± 6.351 36.886 ± 6.558 0.016
NTCP (%) 0.065 ± 0.144 0.017 ± 0.026 0.002 ± 0.005 0.004 ± 0.007 0.049
Organ Volume type 100% Dpf #f a γ50 TD50 (Gy) TCD50 (Gy) Dpf (Gy) α/β (Gy)
PTV Tumor 1.9 35 -10 1 - 28.34 2 1.2
Rectum Normal 1.9 35 8.33 4 80 - 2 3.9
Bladder normal 1.9 35 2 4 80 - 2 8
Abbreviations: 100% Dpf: 100% dose per fraction, #f: number of fractions, α/β: alpha-beta ratio, Dpf: dose per fraction, TD: tolerance dose, 
TCD: tumor control dose.
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